Swiss National Bank Sells 53,100 Shares of Repligen Co. (NASDAQ:RGEN)

Swiss National Bank lessened its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 33.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 103,800 shares of the biotechnology company's stock after selling 53,100 shares during the period. Swiss National Bank owned about 0.19% of Repligen worth $15,448,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Swedbank AB bought a new position in Repligen in the first quarter valued at approximately $5,518,000. Banque Pictet & Cie SA increased its stake in Repligen by 74.6% in the 2nd quarter. Banque Pictet & Cie SA now owns 34,515 shares of the biotechnology company's stock valued at $4,351,000 after buying an additional 14,746 shares during the last quarter. Geneva Capital Management LLC increased its stake in Repligen by 8.5% in the 3rd quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company's stock valued at $20,638,000 after buying an additional 10,908 shares during the last quarter. Diversified Trust Co increased its stake in Repligen by 3.7% in the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company's stock valued at $372,000 after buying an additional 106 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its stake in Repligen by 240.5% in the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company's stock valued at $75,866,000 after buying an additional 425,061 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Repligen Stock Up 0.6 %

Shares of NASDAQ RGEN opened at $142.58 on Friday. The company has a quick ratio of 5.56, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company's fifty day simple moving average is $140.26 and its 200 day simple moving average is $143.44. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $211.13. The firm has a market cap of $7.99 billion, a PE ratio of -385.34, a P/E/G ratio of 4.27 and a beta of 0.96.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same quarter in the prior year, the company posted $0.23 earnings per share. The business's revenue was up 9.7% on a year-over-year basis. As a group, sell-side analysts forecast that Repligen Co. will post 1.52 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on RGEN. Wolfe Research began coverage on shares of Repligen in a research note on Thursday, November 14th. They set a "peer perform" rating on the stock. Stephens restated an "overweight" rating and set a $170.00 price objective on shares of Repligen in a research note on Tuesday, July 30th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $205.00 target price on shares of Repligen in a report on Thursday, September 26th. Benchmark reaffirmed a "hold" rating on shares of Repligen in a report on Monday, August 5th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a report on Wednesday, July 31st. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, Repligen presently has an average rating of "Moderate Buy" and a consensus target price of $190.25.

Insider Activity

In related news, Director Anthony Hunt sold 22,191 shares of the firm's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 1.20% of the stock is currently owned by corporate insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.